We recommend to make use of analysis of Medicenna Therapeutics Corp fundamentals to see if markets are presently mispricing the entity. We were able to break down and interpolate data for twenty-eight available fundamentals for Medicenna Therapeutics, which can be compared to its peers in the industry. The stock experiences a very speculative upward sentiment. Check odds of Medicenna Therapeutics to be traded at C$2.24 in 90 days. Key indicators impacting Medicenna Therapeutics' financial strength include:
Medicenna Therapeutics competes with Aptose Biosciences, Oncolytics Biotech, and Helix BioPharma. Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines and Superkines for the treatment of cancer. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. MEDICENNA THERAPEUTICS operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 7 people.
Foreign Associate
USA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
You should never invest in Medicenna Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Medicenna Stock, because this is throwing your money away. Analyzing the key information contained in Medicenna Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Medicenna Therapeutics Key Financial Ratios
Medicenna Therapeutics' financial ratios allow both analysts and investors to convert raw data from Medicenna Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Medicenna Therapeutics over time and compare it to other companies across industries.
Comparative valuation techniques use various fundamental indicators to help in determining Medicenna Therapeutics's current stock value. Our valuation model uses many indicators to compare Medicenna Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medicenna Therapeutics competition to find correlations between indicators driving Medicenna Therapeutics's intrinsic value. More Info.
Medicenna Therapeutics Corp is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At this time, Medicenna Therapeutics' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Medicenna Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Medicenna Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.
Medicenna Therapeutics Systematic Risk
Medicenna Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Medicenna Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Medicenna Therapeutics correlated with the market. If Beta is less than 0 Medicenna Therapeutics generally moves in the opposite direction as compared to the market. If Medicenna Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Medicenna Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Medicenna Therapeutics is generally in the same direction as the market. If Beta > 1 Medicenna Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Medicenna Therapeutics Corp Total Assets Over Time
Today, most investors in Medicenna Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Medicenna Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Medicenna Therapeutics growth as a starting point in their analysis.
Medicenna Therapeutics December 17, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Medicenna Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Medicenna Therapeutics Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Medicenna Therapeutics Corp based on widely used predictive technical indicators. In general, we focus on analyzing Medicenna Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Medicenna Therapeutics's daily price indicators and compare them against related drivers.
Medicenna Therapeutics financial ratios help investors to determine whether Medicenna Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicenna with respect to the benefits of owning Medicenna Therapeutics security.